Completed PHASE2 INTERVENTIONAL 2-arm NCT01697306

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus-Calmette Guerin (BCG) Instillation Therapy on the Quality of Life in Non-muscle-invasive Bladder Cancer (NMIBC) Patients: Results of a Prospective, Randomised Phase II Trial.

Sponsor: A.O.U. Città della Salute e della Scienza

Conditions Bladder Cancer

Interventions BCG Vaccine Gemcitabine 2 g

Updated 6 times since 2017 Last updated: Jan 28, 2025 Started: Sep 30, 2006 Primary completion: Mar 31, 2011 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01697306, this PHASE2 trial focuses on Bladder Cancer and remains completed. Sponsored by A.O.U. Città della Salute e della Scienza, it has been updated 6 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Feb 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Feb 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

A.O.U. Città della Salute e della Scienza
University of Eastern Piedmont
University of Turin, Italy
Universitätsklinikum Hamburg-Eppendorf

Data source: A.O.U. Città della Salute e della Scienza

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Torino, Italy